Home
Biosimilars treat disabling and potentially life-threatening conditions with no meaningful differences in safety, purity, and potency from their reference drugs.1
Apobiologix is committed to developing cutting-edge biosimilar medicines.
Navigate
About Us
Recent News
Mar 8, 2017
Apobiologix Announces Participation in BBCIC Consortium
Dec 13, 2016
Apobiologix Continues To Move Forward With FDA Review Process
Oct 24, 2016
Dr. Iglesias joins Apobiologix with 25 years of global pharmaceutical R&D experience
- US Food and Drug Administration. Information for consumers (biosimilars). Available at FDA.gov. Accessed August 5, 2015. Page 2, PP 1, 2